AC
ADPT icon

AXQ Capital’s Adaptive Biotechnologies ADPT Stock Holding History

AXQ Capital’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-18,505
Closed -$277K – 708
2025
Q3 		$277K Buy
+18,505
New +$225K 0.11% 345
2023
Q4 		– Sell
-10,600
Closed -$57.8K – 624
2023
Q3 		$57.8K Buy
+10,600
New +$70.1K 0.02% 449

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $34.9B AUM 72.7% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

AXQ Capital's ADPT Position: Q4 2025 in Review

AXQ Capital sold out of Adaptive Biotechnologies (ADPT) in Q4 2025, closing a stake of 18,505 shares — an estimated $277K sold.

AXQ Capital first reported a position in ADPT in Q3 2023 and held it in 2 quarters. The position peaked at $277K in Q3 2025. 283 funds tracked by Wall St. Rank hold ADPT as of Q4 2025.

  • AXQ Capital reported no remaining Adaptive Biotechnologies position as of Q4 2025 after selling out during the quarter.
  • AXQ Capital sold 18,505 Adaptive Biotechnologies shares in Q4 2025, an estimated $277K.
  • AXQ Capital first reported a position in Adaptive Biotechnologies in Q3 2023 and held it in 2 quarters.
  • AXQ Capital's Adaptive Biotechnologies position peaked at $277K in Q3 2025.
  • 283 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q4 2025.

Based on AXQ Capital's 13F filing for Q4 2025, filed 10 Feb 2026.